High throughput viral titering of AAV throughout the production continuum
Aug
4
2022
On demand

High throughput viral titering of AAV throughout the production continuum

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
High throughput viral titering of AAV throughout the production continuum

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Process development for viral vector manufacturing relies on accurate titers to inform critical decisions. Digital PCR is the established titer method to support AAV manufacturing, but droplet-based methods have historically been challenged by matrix effects and long time to data. Please join us to learn how the Center for Breakthrough Medicines (CBM) has applied nanoplate-based QIAcuity digital PCR technology to achieve accurate titers from multiplexed assays with challenging samples.

What you will learn:

  • How new advances in digital PCR provide more data, across more sample types, faster, and with higher throughput: 
  • Critical factors to consider when choosing automated platforms for AAV viral titer determination 
  • Strategies to efficiently quantify more targets in the same sample 
  • Pushing past common droplet busting matrices to expand testing throughout the AAV process continuum
Kelly Geosits
Kelly Geosits
Associate Scientist at

Kelly Geosits is a Research & Development Associate Scientist at Center for Breakthrough Medicine. Kelly graduated from the University of the Sciences in Philadelphia with a BS in Microbiology in 2014. Her undergraduate research focused on microtubule dynamics in the cytoskeleton. After graduation, she worked on research projects at Hahnemann Hospital through Drexel College of Medicine focusing on paracrine signaling in metastatic pancreatic ductal adenocarcinoma. Kelly had brief sales roles before working at Puresyn, a plasmid DNA manufacturer, where she worked in purification and eventually in quality assurance. She is thrilled to be back in a laboratory research setting focusing on Upstream Process Development for AAV gene therapy.

SPEAKERS

Kelly Geosits
Kelly Geosits
Associate Scientist at

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual
27 June
in 70
Days
Register
Pure and simple: understanding LNP analytics for better mRNA-based drugs

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe
29 May
in 41
Days
Register
Empowering patient care: in-process and quality control solutions for cellular therapies

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz
23 May
in 35
Days
Register
T cells from beginning to end: optimizing leukopak and drug product cryopreservation

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity
22 May
in 34
Days
Register
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes
21 May
in 33
Days
Register